Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

DECAMP 1 PLUS: Prediction of Lung Cancer Using Noninvasive Biomarkers
DECAMP 1 PLUS: Prediction of Lung Cancer Using Noninvasive Biomarkers

NCT04165564

Active Not RecruitingN/A

Sponsor: Boston University

Conditions: Pulmonary Disease

Interventions: Institutional standard of care, Biosamples of airway and blood

Countries: United States

DECAMP 1 PLUS aims to improve the efficiency of the diagnostic evaluation of patients with indeterminate pulmonary nodules (8-25 mm). Molecular biomarkers for lung cancer diagnosis measured in minimally invasive and non-invasive biospecimens may be able to distinguish between malignant or benign indeterminate pulmonary nodules in high-risk smokers. Ultimately, this study aims to validate molecular as well as clinical and imaging biomarkers of lung cancer in individuals with indeterminate lung nodules.

Eligibility overview

Sex: ALL

Age: 46 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria
Inclusion Criteria:

* Radiologic diagnosis of solid indeterminate pulmonary nodule (0.8 to 2.5 cm) identified in the past 3 months OR semi-solid (mixed density) nodule with solid component of at least 0.6 cm identified in the past 12 months; must be of appropriate size at enrollment.
* CT scan completed within 3 months prior to enrollment
* Able to tolerate all biospecimen collection as required by protocol
* Able to comply with standard of care follow up visits including clinical exams, diagnostic work-ups, and imaging for approximately three years from enrollment
* Able to complete the Patient Lung History questionnaire with study staff

Arm 1 - Screening

* Age 55-77 years old
* Current and former smokers with 30 pack-years or more(and quit less than 15 years ago)

Arm 2 - Incidental

* Age \> 45 years old
* Current and former smokers with 10 pack-years or more(and quit less than 15 years ago)

Exclusion Criteria:

* History or previous diagnosis of primary lung cancer, metastatic lung cancer, or any other non-lung cancer within 5 years (not including non-melanoma skin cancer)
* Symptoms of lung cancer (unexplained weight loss 10 lbs or more in 3 months, recent hemoptysis)
* Diagnosis of pure ground glass opacities for the target lesion on chest CT within the last 12 months (i.e., mixed features on the target lesion and pure ground glass opacity on non-target lesions are acceptable as mentioned above)
Locations (19)
  • Birmingham, Alabama, United States
  • Los Angeles, California, United States
  • Los Angeles, California, United States
  • San Diego, California, United States
  • Iowa City, Iowa, United States
  • Bethesda, Maryland, United States
  • Boston, Massachusetts, United States
  • Ann Arbor, Michigan, United States
  • Rochester, Minnesota, United States
  • Cleveland, Ohio, United States
  • Philadelphia, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • Providence, Rhode Island, United States
  • Nashville, Tennessee, United States
  • Houston, Texas, United States
  • Portsmouth, Virginia, United States
  • Morgantown, West Virginia, United States